Richard Love - PAREXEL International Independent Director

  Director
Mr. Richard L. Love is an Independent Director of Parexel International Corporationrationration. is a member of the Compensation Committee, the Nominating and Corporationrationrate Governance Committee and the Human Resources Committee. Since January 2007, Mr. Love has served as a partner of Translational Accelerator Venture Fund, an investment fund. Since October 2016, he has served as Interim President and Chief Executive Officer of CTI Biopharma, Inc., a biopharmaceutical company. From January 2003 to January 2007, he served as Chief Operating Officer of Translational Genomics Research Institute, a medical research organization, and from January 2002 to December 2004, he served as a director of ILEX Oncology, an oncology focused pharmaceutical company. From October 1994 to January 2002, Mr. Love served as President and Chief Executive Officer of ILEX Oncology. From 1991 to 1994, he served as Chief Operating Officer of the Cancer Therapy and Research Center, a cancer treatment center focused on the clinical evaluation of new agents. From 1983 to 1991, Mr. Love served as Chief Executive Officer of Triton Biosciences, Inc., a biotechnology company. Mr. Love currently serves as a director of CTI Biopharma, Inc., SyndevRx Inc., Applied Microarrays Inc., Cancer Prevention Pharmaceuticals, Inc. and CerRx Inc., and as a Manager on the Board of Managers of PMED Management LLC.
Age: 72  Director Since 2002      
781 487-9900  http://www.parexel.com

Richard Love Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Geoffrey ParkerPerrigo Company Plc
2016
Louise ParentZoetis
2013
Theodore SamuelsPerrigo Company Plc
2017
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Jacqualyn FousePerrigo Company Plc
2012
Bruce CarterDr Reddys Laboratories Ltd
2008
Anthony ColesRegeneron Pharmaceuticals
2017
George SingRegeneron Pharmaceuticals
1988
Sanjay KhoslaZoetis
2013
Arthur RyanRegeneron Pharmaceuticals
2003
J MoreauDr Reddys Laboratories Ltd
2007
Jeffrey KindlerPerrigo Company Plc
2017
Michael BrownRegeneron Pharmaceuticals
1991
Herman MorrisPerrigo Company Plc
1999
William YoungVertex Pharmaceuticals Incorpor
2014
Geoffery MerszeiOrigin Agritech Limited
2016
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Allan ObermanDr Reddys Laboratories Ltd
2019
Michael TrimbleOrigin Agritech Limited
2006
William SteereZoetis
2013

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Currently Active Assets on Macroaxis

PASS   
Purchased over 200 shares of
a day ago
Traded for 14.76
FSLR   
Purchased over 50 shares of
a day ago
Traded for 53.37
AAPL   
Purchased few shares of
a day ago
Traded for 270.71
C   
Purchased over 40 shares of
a day ago
Traded for 75.81
VMW   
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try CEO Directory module to screen ceos from public companies around the world.
Search macroaxis.com